# Comparative Immunogenicity Study of Multiple Doses of Proposed Pegfilgrastim Biosimilar, INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects.

> **NCT04015232** · PHASE1 · COMPLETED · sponsor: **Intas Pharmaceuticals, Ltd.** · enrollment: 200 (actual)

## Conditions studied

- Immunogenicity
- Healthy Volunteers

## Interventions

- **COMBINATION_PRODUCT:** INTP5
- **COMBINATION_PRODUCT:** US Neulasta

## Key facts

- **NCT ID:** NCT04015232
- **Lead sponsor:** Intas Pharmaceuticals, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-26
- **Primary completion:** 2018-06-05
- **Final completion:** 2018-06-05
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2019-10-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04015232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04015232, "Comparative Immunogenicity Study of Multiple Doses of Proposed Pegfilgrastim Biosimilar, INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04015232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*